Cytokinetics (CYTK)

Company Profile

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.

Company profile

Ticker

CYTK

Exchange

NASDAQ

Website

cytokinetics.com/

CEO

Robert Blum

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

SEC CIK

0001061983

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

IRS number

943291317

CYTK stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

3 Aug 23

Cytokinetics Reports Second Quarter 2023 Financial Results

Submission of Matters to a Vote of Security Holders

5 May 23

Cytokinetics Reports First Quarter 2023 Financial Results

4 May 23

ARS

2022 FY

Annual report to shareholders

Transcripts

View all

CYTK

Earnings call transcript

2023 Q2

3 Aug 23

CYTK

Earnings call transcript

2023 Q1

4 May 23

CYTK

Earnings call transcript

2022 Q4

1 Mar 23

CYTK

Earnings call transcript

2022 Q2

7 Aug 22

CYTK

Earnings call transcript

2022 Q1

5 May 22

CYTK

Earnings call transcript

2021 Q4

25 Feb 22

CYTK

Earnings call transcript

2021 Q3

4 Nov 21

CYTK

Earnings call transcript

2021 Q2

6 Aug 21

CYTK

Earnings call transcript

2021 Q1

7 May 21

CYTK

Earnings call transcript

2020 Q4

26 Feb 21

Latest ownership filings

View all

144

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

25 Aug 23

144

Notice of proposed sale of securities

Notice of proposed sale of securities

11 Aug 23

Robert I Blum

11 Aug 23

Financial summary

Financial statements Chart CYTK financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	69.01 mm	69.01 mm	69.01 mm	69.01 mm	69.01 mm	69.01 mm
Cash burn (monthly)	11.40 mm	2.05 mm	40.68 mm	40.17 mm	40.60 mm	35.53 mm
Cash used (since last report)	34.54 mm	6.21 mm	123.25 mm	121.68 mm	123.00 mm	107.63 mm
Cash remaining	34.48 mm	62.80 mm	-54.24 mm	-52.67 mm	-53.99 mm	-38.61 mm
Runway (months of cash)	3.0	30.6	-1.3	-1.3	-1.3	-1.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

CYTK institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	252	258	-2.3%
Opened positions	31	34	-8.8%
Closed positions	37	52	-28.8%
Increased positions	95	81	+17.3%
Reduced positions	79	95	-16.8%

13F shares	Current	Prev Q	Change
Total value	3.52 tn	3.75 tn	-6.3%
Total shares	116.59 mm	115.76 mm	+0.7%
Total puts	287.20 k	191.00 k	+50.4%
Total calls	187.90 k	192.60 k	-2.4%
Total put/call ratio	1.5	1.0	+54.1%

Largest owners	Shares	Value	Change
BLK Blackrock	15.36 mm	$501.11 bn	+5.0%
FMR	12.16 mm	$396.76 bn	-5.5%
Vanguard	10.27 mm	$335.03 bn	+0.9%
Wellington Management	8.27 mm	$269.79 bn	+9.9%
STT State Street	5.09 mm	$166.09 bn	+7.1%
Eastern Capital	3.06 mm	$64.35 mm	0.0%
Biotechnology Value Fund L P	2.73 mm	$54.56 mm	0.0%
American Century Companies	2.72 mm	$88.88 bn	+1.7%
Polar Capital	2.65 mm	$86.59 bn	+1.6%
RTW Investments	2.57 mm	$83.97 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
BAC Bank Of America	260.98 k	-942.28 k	-78.3%
Farallon Capital Management	21.77 k	-916.30 k	-97.7%
Citadel Advisors	899.99 k	+899.99 k	NEW
Wellington Management	8.27 mm	+744.18 k	+9.9%
BLK Blackrock	15.36 mm	+736.79 k	+5.0%
FMR	12.16 mm	-701.84 k	-5.5%
Lord, Abbett & Co.	1.69 mm	-616.80 k	-26.7%
JHG Janus Henderson	2.10 mm	+522.06 k	+33.2%
Millennium Management	516.47 k	+516.47 k	NEW
Marshall Wace	255.39 k	-489.92 k	-65.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CYTK insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Sep 23	Fady Ibraham Malik	Common Stock	Sell	Dispose S	No	No	34.86	2,500	87.15 k	155,664
13 Sep 23	Robert I Blum	Common Stock	Sell	Dispose S	No	No	34.8965	12,500	436.21 k	441,417
13 Sep 23	Robert I Blum	Common Stock	Option exercise	Acquire M	No	No	6.67	12,500	83.38 k	453,917
13 Sep 23	Robert I Blum	NQSO Common Stock	Option exercise	Dispose M	No	No	6.67	12,500	83.38 k	243,494
25 Aug 23	Robert I Blum	Common Stock	Sell	Dispose S	No	No	33.99	12,500	424.88 k	441,417
25 Aug 23	Robert I Blum	Common Stock	Option exercise	Acquire M	No	No	7.96	10,000	79.60 k	453,917
25 Aug 23	Robert I Blum	Common Stock	Option exercise	Acquire M	No	No	6.67	2,500	16.68 k	443,917
25 Aug 23	Robert I Blum	Incentive Stock Option Common Stock	Option exercise	Dispose M	No	No	7.96	10,000	79.60 k	0
25 Aug 23	Robert I Blum	NQSO Common Stock	Option exercise	Dispose M	No	No	6.67	2,500	16.68 k	255,994
21 Aug 23	Wierenga Wendall	Common Stock	Sell	Dispose S	No	No	32.02	6,020	192.76 k	18,205